B.H.L.
Alright as we all know thyroid nodules, benign ones, are very common in our population and the majority of them don't need any treatment. But we know that about 10% of nodules will get big over time. For those that are sized more than 4cm in diameter or those who are causing symptoms, obstructive symptoms or pressure symptoms. The situation when surgery is generally indicated. As a surgeon this is a very common problem for me and that's the reason to look at. But because surgery has risks and we try to look at less invasive way of treating nodules. So we try to preserve those who have benign problems with less invasive option. I think high-intensity focused ultrasound is one minimally invasive option for treatment of benign thyroid nodules.
D.C.M.
Okay thanks. So there are now many ablative technologies available including RFA, microwave ablation, laser ablation, chemical ablation, cryoablation, SBRT, HIFU which you've already alluded to, and irreversible electroporation. So many of these technologies have already been used to successfully treat benign thyroid nodules, why was HIFU specifically chosen for your study?
B.H.L. I think high-intensity focused ultrasound is an attractive option for patients generally, because most of these patients are females. Obviously for other techniques such as radio frequency ablation or laser ablation or other ablation techniques they only need a needle to be inserted into through the skin and into the nodule. And that's very minimally invasive but nevertheless you know you still need to puncture the skin. What HIFU or high-intensity focused ultrasound can do is can ablate an area without ever puncturing the skin and I think that is an attractive way of treating nodules. Also our patients who come in for treatment they actually don't need to change, just wear the normal clothes, they come into our treatment room, have the treatment and then they go home within hours after treatment. And so I think that's, for me, that is probably the least invasive way of treating the nodules. And also as you are aware there are of course multiple, many applications on radiofrequency ablation, laser ablation, but there has been very few studies on high-intensity focus ultrasound and that's the reason why our centers really want to focus on this area. Just for your information, we have been treating high-intensity focus ultrasound liver lesions as well as well as uterine lesions. So this is not new for us. The liver lesions we have been treating for over 10 years. I don't do it personally, but my colleagues they do the liver ablation and for me I do the thyroid ablation because this is part of the endocrine surgery. So my breast colleagues are using the same machines for the breast lesions. This is what we like to do over here and that's why we're doing it. D.C.M. Well thanks. Can you just explain the technology and the mechanisms of action of HIFU since many in our audience may not be all that familiar? B.H.L. To put it in very simple terms, basically it's about focusing an ultrasound beam into a very small focal area underneath the skin. The depth of treatment is usually around 1 to 2 cm. If it's too close to the skin then you worry about burning the skin. The wave length of, the (inaudible) wave is obviously a low frequency transmission. It's an ultrasound guided treatment so it's real time imaging focusing an area, and so for a nodule around 3cm the machine actually can actually divide the nodules into different subunits and automatically ablate the area. As long as we achieve a certain temperature change around 55 to 65 degrees, then we will have irreversible tissue damage. With damage over time the nodule shrinks. It's really similar to other ablation techniques I suppose. B.H.L. The hypothesis was that, well previous studies have shown that ablation will shrink the nodules, so it's not surprising that applying for HIFU the nodule will shrink. What we're trying to show is that not only the nodule shrinks, but patients feel better. That is feel better and quality of life will improve as a result of the shrinkage. I think in our study we have two groups of patients, although not randomized. One group had the HIFU ablation; the other group just has surveillance over a 12 month period. As we expected, we found that those who had ablation the symptom score improved relative to the controls and also the quality of life was improved.
(inaudible) that we got from the ablation, physical shrinkage, there was also a symptom improvement as well as a quality of life improvement.
So how are patients actually selected for participation in your study? And what were the symptoms, laboratory studies, and imaging criteria used in the selection process?
B.H.L. Right. Patients were, well first of all they need to have to benign in nature, so we will do a fine-needle aspiration before -at the first assessment to see if they are benign nodules. That is a Tesla 2 on cytology and also these patients are symptomatic which means that they complaining of either pressure or some sort of choking sensation we asked them; and also patients who didn't want surgery. So these are the patients who were reluctant for surgery that we would offer ablation or observation and it's up to them to choose. And over that period of time were at 22 patients who would desire to have treatment and 22 patients who desire not to have treatment. And we just followed them up through the 12 months and the results are showing in the papers.
So was there any specific laboratory values that you were looking for, any imaging findings that would make one be more likely to do HIFU as opposed to any other kind of therapy?
B.H.L. Okay. Imaging-wise apart from the cytology of course I think the nodules needs to be needs to have a low suspicion pattern which means they are (inaudible) and also they have to be well circumscribed, no suspicious features or malignancy for ablation. Does that answer your question? D.C.M. Yes, that was very good. Thanks. Just to I guess you had already.
B.H.L. (inaudible) blood test all the patients have to
be new fibroid that means the thyroid function has to be within the normal range.
D.C.M.
Okay, so in terms of you had basically you had a brief overview of your results, but could you be a little more specific in what was actually found in terms of your results?
B.H.L. Okay, specifically I think in terms of nodule shrinkage the median, if I remember correctly, the shrinkage was around 70% in volume as compared to the baseline and also we found the symptoms in terms of pressure symptoms improved, and also the physical component of the health-related quality of life was improved from baseline as compared to the controls. B.H.L. Specifically there were either -they had -before treatment they had symptoms. When they lie flat they feel the pressure on the neck when they lie flat or sometimes when they try to swallow fluids, occasionally they have fluid regurgitating up so kind of choking, but it's intermittent, it's occasional.
So in patients that had more than one nodule because that often happens, how did you determine which nodule to actually treat?
B.H.L. That's a very good question.

D.C.M. Assuming only one nodule was treated.
B.H.L. I think if I remember correctly about half of our patients had dominant nodule in a much larger goiter. So we would normally treat the dominant nodule in terms of -the dominant nodule probably would have caused the most symptoms. (Inaudible) D.C.M. Okay, given that HIFU requires extreme precision, was this study performed under general anesthesia or moderate sedation and to that end how long do these HIFU sessions typically last?
B.H.L.
We didn't use general anesthesia, we used moderate IV sedation. The patients had a bit of pain. So they weren't absolutely pain free. We asked about pain during treatment and most of them had pain, but the pain was tolerable, so in our series none of them were not able to complete treatment because of pain. It wasn't general anesthesia. The kind of medicine we give was IV (inaudible) and (inaudible) which is a <benzodiazepine>. We found that an analgesia was more important so we give a high dose of analgesia. Sedation we didn't want to give too much because that would affect the respiration. One other problem is if we give too much sedation is patients tend to have more heavier breathing and that could cause movement of the thyroid and that makes the treatment difficult and so the sedation is, the analgesia and the sedation is tricky to get the right balance. Typically the treatment takes around 45 to an hour depending on the size of the nodule. For most of the nodules around 3 to 4cm it would take about 45 minutes. 
In our series about half of our patients had some sort of redness some swelling in the ablation sites and that's not uncommon because as the analgesic goes through the skin into nodule the skin and the subcutaneous tissue and muscle actually absorb some of the analgesic and we think that's the reason why you have neck swelling at least for the first few days. And that's why usually we apply ice packing for the first few days, for the first few hours and after they go home they can also apply ice packing. We think that helps with the swelling, but none of them had any skin burn. We didn't have anybody with skin burn. Potentially they could have vocal cord palsy. (Inaudible) nerve (inaudible) lies along tracheoesophageal groove If the nodule is very close or part of it is very close to the tracheoesophageal groove it's possible you can get damage of the (inaudible) nerve and causing hoarseness of voice or vocal cord palsy.
D.C.M.
So how difficult is it to identify the parathyroid gland given that you're kind of in the same region?
B.H.L. Yes it's almost impossible because a normal parathyroid gland you won't see on ultrasound. An abnormal one yes of course you'd see but for a normal one you don't see. Fortunately we have four parathyroid glands and so it's pretty difficult to damage all four parathyroid glands because (inaudible.) D.C.M. Okay great. So your study compared HIFU to active surveillance but not to any other ablative technology. How would you think that HIFU would have compared to other percutaneous methods that have already been tried?
B.H.L. I think that in terms of (inaudible) actually the radio frequency ablation or laser ablation or other ablation technique would be more efficient in terms of I guess the energy would bypass the skin and the (inaudible) the nodule and so that's why the treatment time would be much shorter than say high-intensity focused ultrasound. We do look at literature the treatment time for similar size nodule by radio frequency ablation or laser ablation it takes roughly 15 to 20 minutes, whereas for high-intensity focused ultrasound takes about an hour. It's almost a double or triple time difference. But mostly that's because the machine is at the moment is very safe. It tries to cool the skin so actually the treatment time actually is quite short, but in between the treatment, the process there are quite a long cooling time period. That's why the entire treatment time is actually long. The actual process actually is not really long. I suppose with the update on the software probably they can improve on the treatment time. I'm quite confident that we can shorten the treatment time by about half if we can shorten the cooling period.
D.C.M. Okay thanks. What were the limitations of your study?
B.H.L. Well I think firstly it's not a randomized study. So as you will see when you look at the baseline comparison between the two groups of patients obviously those who had bigger nodules will tend to get treatment, while those who had smaller nodules would have surveillance. It's difficult to do a randomized study because patients who are offered this treatment would tend to opt to have the treatment rather than to observe and do nothing. At least that's my experience so far with patients. But nevertheless I think this is one of the bias and this may cause -this may affect the outcomes of the study because obviously those who get treated would like the treatment to help them and so maybe that's maybe an explanation why they quality of life improved as well. I think the non-randomization is one of the shortcomings of the study. The study is relatively small I must say. It's only 44 patients and a 22 patient group, although we did do a calculation and it seems 20 patients, 22 patients were enough for to achieve (inaudible) for the study but nevertheless a bigger study or even a multi-center study would be more convincing I would say because the technology at the moment is done by very few centers. We are one of them and it would be nice to have a bigger multi-center study and to see if we can repeat the same results. B.H.L. I think one of the big areas to study, if you look at results, about 20% of nodules actually don't shrink enough in the 6 to 12 months and we don't know exactly why that's the reason. We try to obviously since the study we have done about 120 treatments actually and we try to collect data to see whether there's a particular kind of nodule or whether it's the position or the power we use. I think the other things might predict who respond well to this treatment and who would not respond well to this treatment. That's important information for patients to know so that for some patients we can select them this technology and for others that may be less responsive, maybe they should offer other thermal ablation or even surgery. D.C.M. Well great. So Dr. Lang I would like to thank you for joining me today on this podcast to discuss your groups clinical work comparing HIFU to active surveillance for the management of symptomatic benign thyroid nodules. I definitely thought the discussion was very insightful and should give our viewers a good platform to understand the use of this exciting technology to treat symptomatic benign thyroid nodules as well potentially other solid lesions. We are looking forward to seeing your group's future work. Thank you again.
B.H.L. Thanks very much.
